Citations

Clear

1134 citation(s) found for "Yan, Su".

Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
Chatterjee, Pratishtha , Vermunt, Lisa , Gordon, Brian A. , Pedrini, Steve , Boonkamp, Lynn, Armstrong, Nicola J. , Luo, Jingqin , Singh, Abhay Kumar , Li, Yan , Sohrabi, Hamid R. , Taddei, Kevin , Berman, Sarah , Chhatwal, Jasmeer P. , Graff-Radford, Neill, Day, Gregory S. , Farlow, Martin, Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Xiong, Chengjie , Perrin, Richard J. , Fagan, Anne M. , Morris, John C. , Gordon, Brian A , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Luo, Jingqin , Berman, Sarah , Boonkamp, Lynn , Molloy, Mark P. , Benzinger, Tammie L.S. , Morris, John , Karch, Celeste M. , Cruchaga, Carlos , Farlow, Martin R. , Lee, Jae Hong , McDade, Eric , Mori, Hiroshi , Sánchez‐Valle, Raquel , Schofield, Peter R. , Levey, Allan I. , Jucker, Mathias , Masters, Colin L. , Bateman, Randall J. , Martins, Ralph N. , Teunissen, Charlotte E.

Mayo Clinic

No container title available | July 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1752559/v2 Get It

Abstract Glial fibrillary acidic protein (GFAP) is a promising candidate blood-based biomarker for Alzheimer’s disease (AD) diagnosis and prognostication. The timing of its disease-associated changes, its clinical correlates, and biofluid-type dependency will influence its clinical utility. We evaluated plasma, serum, and CSF GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Plasma GFAP elevations appear a decade before expected symptom onset, after β-amyloid accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished β-amyloid-positive from β-amyloid-negative ADAD participants and showed a stronger relationship with β-amyloid load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Our findings support a role for plasma GFAP as a clinical biomarker for β-amyloid-associated cognitive deterioration in AD.
SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice
Dinnon, Kenneth H. , Leist, Sarah R. , Dang, Hong , Fritch, Ethan J. , Gully, Kendra L. , Cruz, Gabriela De la , Evangelista, Mia D. , Asakura, Takanori , Gilmore, Rodney C. , Hawkins, Padraig, Nakano, Satoko , West, Ande , Schäfer, Alexandra, Gralinski, Lisa E. , Zweigart, Mark R. , Dong, Stephanie , McBride, Jennifer , Cooley, Michelle R. , Hines, Jesse B., Love, Miriya K., Groshong, Steve D. , VanSchoiack, Alison , Phelan, Stefan, Liang, Yan , Hether, Tyler , Zumwalt, Ross E., Barton, Lisa M., Duval, Eric J., Stroberg, Edana , Borczuk, Alain , Thorne, Leigh B., Sakthivel, Muthu , Lee, Yueh Z. , Mock, Jason R. , Seibold, Max A. , O’Neal, Wanda K. , Montgomery, Stephanie A. , Boucher, Richard C. , Okuda, Kenichi , Dang, Hong , Fritch, Ethan J , Gully, Kendra L , De la Cruz, Gabriela , Evangelista, Mia D , Asakura, Takanori , Gilmore, Rodney C , Nakano, Satoko , West, Ande , Schäfer, Alexandra , Gralinski, Lisa E , Everman, Jamie L , Sajuthi, Satria P , Dong, Stephanie , McBride, Jennifer , Cooley, Michelle R , Groshong, Steve D , VanSchoiack, Alison , Phelan, Stefan J , Liang, Yan , Hether, Tyler , Leon, Michael , Sakthivel, Muthu K , Lee, Yueh Z , Hagood, James S , Mock, Jason R , Seibold, Max A , O'Neal, Wanda K , Montgomery, Stephanie A , Boucher, Richard C , Baric, Ralph S , Mukhopadhyay, Sanjay

Mayo Clinic

Science Translational Medicine | July 7, 2022 | Volume: 14 | Issue: 664 | Pages: No page available

10.1126/scitranslmed.abo5070 | PMID 35857635 Get It

A subset of individuals who recover from coronavirus disease 2019 (COVID-19) develop post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC), but the mechanistic basis of PASC-associated lung abnormalities suffers from a lack of longitudinal tissue samples. The mouse-adapted SARS-CoV-2 strain MA10 produces an acute respiratory distress syndrome in mice similar to humans. To investigate PASC pathogenesis, studies of MA10-infected mice were extended from acute to clinical recovery phases. At 15 to 120 days after virus clearance, pulmonary histologic findings included subpleural lesions composed of collagen, proliferative fibroblasts, and chronic inflammation, including tertiary lymphoid structures. Longitudinal spatial transcriptional profiling identified global reparative and fibrotic pathways dysregulated in diseased regions, similar to human COVID-19. Populations of alveolar intermediate cells, coupled with focal up-regulation of profibrotic markers, were identified in persistently diseased regions. Early intervention with antiviral EIDD-2801 reduced chronic disease, and early antifibrotic agent (nintedanib) intervention modified early disease severity. This murine model provides opportunities to identify pathways associated with persistent SARS-CoV-2 pulmonary disease and test countermeasures to ameliorate PASC.
Uvular Necrosis: A Rare Complication After Esophagogastroduodenoscopy in an Intubated Patient
Bhatia, Unnati , Barrett, Stevi , Bajaj, Suryansh , Bi, Yan

Mayo Clinic

ACG Case Reports Journal | July 1, 2022 | Volume: 9 | Issue: 7 | Pages: e00795

10.14309/crj.0000000000000795 | PMID 35784500 Get It

ABSTRACT Uvular necrosis is a potential etiology of postesophagogastroduodenoscopy persistent sore throat and odynophagia, and physicians should be alert to the possibility of this potential complication. Diagnosis is clinical and can be made on the basis of symptoms and characteristic findings on oropharyngeal examination. It has a benign course with an overall good clinical outcome. Conservative symptomatic management is the treatment of choice, and full recovery can be expected in 2 weeks. Keeping oropharyngeal instruments and ventilation tubes to the side of the midline, avoidance of blind suctioning, and decreasing the power of suction devices are some of the measures, which might reduce the risk of intraprocedure uvular injury. In addition, it is important to note that the risk of injury is higher in some individuals, for instance, patients with a long uvula, and it might be beneficial to take extra precautions in these patients.
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
Chatterjee, Pratishtha , Gordon, Brian A. , Boonkamp, Lynn , Armstrong, Nicola J. , Xiong, Chengjie , Li, Yan , Taddei, Kevin , Chhatwal, Jasmeer P. , Graff‐Radford, Neill R. , Farlow, Martin R. , Mori, Hiroshi , Perrin, Richard J. , Fagan, Anne M. , Gordon, Brian A , Vermunt, Lisa , Pedrini, Steve , Singh, Abhay Kumar , Sohrabi, Hamid R. , Molloy, Mark P. , Benzinger, Tammie L.S. , Morris, John C. , Karch, Celeste M. , Berman, Sarah , Day, Gregory S. , Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Lee, Jae‐Hong , Xiong, Chengjie , McDade, Eric , Sánchez‐Valle, Raquel , Schofield, Peter R. , Jucker, Mathias , Masters, Colin L. , Bateman, Randall J. , Martins, Ralph N. , Teunissen, Charlotte E.

Mayo Clinic

No container title available | June 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1752559/v1 Get It

Abstract Glial fibrillary acidic protein (GFAP) is a promising candidate blood-based biomarker for Alzheimer’s disease (AD) diagnosis and prognostication. The timing of its disease-associated changes, its clinical correlates, and biofluid-type dependency will influence its clinical utility. We evaluated plasma, serum, and CSF GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Plasma GFAP elevations appear a decade before expected symptom onset, after β-amyloid accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished β-amyloid-positive from β-amyloid-negative ADAD participants and showed a stronger relationship with β-amyloid load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Our findings support a role for plasma GFAP as a clinical biomarker for β-amyloid-associated cognitive deterioration in AD.
Abstract 3913: Quantitative phosphoproteomic analysis of AXL signaling network in breast cancer
Pearson, Nicole A, Xiong, Yuning, Wu, Xin‐Yan , Wang, Li , Renuse, Santosh , Cheng, Ran, Carter, Jodi M. , Pandey, Akhilesh , Wu, Xinyan

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 3913-3913

10.1158/1538-7445.am2022-3913 Get It

Abstract Background: As a key receptor tyrosine kinase (RTK) regulating tumorigenesis, AXL is overexpressed in multiple different types of cancers. AXL can be activated by homodimerization after binding with its ligand, growth arrest specific 6 protein (Gas6) or by heterodimerization with other RTKs. AXL overexpression and/or activation have been reported to promote cancer cell proliferation, migration/invasion and to induce resistance to targeted therapy. However, the AXL downstream signaling network has not yet been fully elucidated. Methods: We employed a CRISPR-CAS9-based knockout technology to create AXL inducible knockout cells in a human triple negative breast cancer (TNBC) cell line, HCC1395. In order to explore the downstream signaling events driven by AXL, we induced AXL knockout for 72 hours and used a 6-plex TMT-labeling-based quantitative proteomic approach to characterize the protein phosphorylation alterations induced by AXL knockout. IMAC and anti-phosphotyrosine antibody (pY1000)-based phosphopeptide enrichment methods were used to comprehensively quantify the phosphoproteome changes induced by AXL knockout. Results: In this study, we identified 38,525 phospho serine/threonine sites and 1,427 phosphotyrosine sites. In response to AXL knockout, 1,581 phospho serine/threonine sites and 40 phosphotyrosine sites showed significant differences between AXL-KO and AXL-WT groups with >1.5-fold change and p<0.05 as the cutoff. Among them, 982 phosphoserine/threonine sites and 30 phosphotyrosine sites were decreased, while 599 phospho serine/threonine sites and 10 phosphotyrosine sites were increased in AXL-KO cells. Signaling pathway enrichment analysis revealed that suppressing AXL expression could inhibit multiple important cancer related signaling pathways, including cell cycle, focal adhesion, MAPK signaling pathway, p53 signaling pathway and mTOR signaling pathway. Conclusion: Quantitative analysis of the phosphoproteome driven by AXL demonstrated that AXL plays a pivotal role in regulating canonical oncogenic signaling but also signaling pathways involved in RNA processing and DNA repair. Our data also suggest that targeting AXL could suppress these oncogenic signaling pathways and have therapeutic potential to improve clinical outcomes for patients with AXL overexpression. Citation Format: Li Wang, Nicole Pearson, Yuning Xiong, Santosh Renuse, Ran Cheng, Jodi M. Carter, Akhilesh Pandey, Xinyan Wu. Quantitative phosphoproteomic analysis of AXL signaling network in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3913.
Abstract 2855: Antitumor activity of BAFF-R targeting CAR T-cells on chronic lymphocytic leukemia
Luo, Yan , Lui, Kaihin, To, Tommy, liu, Andrew, Dabaja, Mohamed A. Kharfan, Qin, Hong , Yassine, Farah , Gadd, Martha E.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: 2855-2855

10.1158/1538-7445.am2022-2855 Get It

Abstract B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in adults with CD19-targeting CAR T-cell therapy showing an excellent initial curative response. However, 10-20% of patients who receive anti-C19 CAR T-cell treatment experience relapse due to CD19 antigen loss. B-cell activating factor receptor (BAFF-R) that is expressed on the surface of normal and neoplastic B cells mediates the survival of mature peripheral B cells along with the B-cell receptor. Since B-CLL is characterized by apoptotic disruption and subsequent accumulation of mature B cells, BAFF-R is a logical, novel target for CAR T-cell therapy directed against B-CLL, especially if CD19 antigen loss occurs. In this study, we first manufactured BAFF-R CAR T-cells by infecting healthy donor Tnaïve/memory (Tn/mem) cells with BAFF-R CAR lentivirus before evaluating the antitumor activity of BAFF-R CAR T-cells on wild type MEC-1 (a B-CLL cell line), modified MEC-1, and primary cell lines. Antigen-specific cytotoxicity and activation of the BAFF-R CAR T-cells or control CD19 CAR T-cells were determined upon incubation with B-CLL cell lines and patient-derived primary B-CLL by measuring degranulation and IFN-γ release, respectively. BAFF-R CAR T-cells demonstrated substantial cytotoxicity against MEC-1, CD19-deficient MEC-1, and primary B-CLL cell lines; CD19 CAR T-cells showed no effect on CD19-deficient MEC-1 cells but did show effects with primary B-CLL and MEC-1 cells. Similarly, the release of IFN-γ was greater when BAFF-R CAR T-cells were co-cultured with CD19-deficient MEC-1 or primary B-CLL compared to CD19 CAR T-cells co-cultured with CD19-deficient MEC-1. In summary, BAFF-R CAR T-cells exert significant antitumor properties not only on patient-derived primary B-CLL cells but also on a CD19-deficient B-CLL cell line. We, therefore, assert BAFF-R-targeting CAR T-cells to be a novel therapeutic avenue for patients newly diagnosed with B-CLL and patients experiencing relapsed B-CLL after anti-CD19 therapy. Citation Format: Yan Luo, Kaihin Lui, Tommy T. To, Andrew liu, Farah Yassine, Mohamed A. Kharfan Dabaja, Martha E. Gadd, Hong Qin. Antitumor activity of BAFF-R targeting CAR T-cells on chronic lymphocytic leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2855.
A novel humanized PD-1/PD-L1 mouse model permits direct comparison of anti-tumor immunity generated by FDA-approved PD-1 and PD-L1 inhibitors
Liu, Xin , Harrington, Susan M. , Hirdler, Jacob B. , Gicobi, Joanina K. , Zhu, Xingxing , Yan, Yiyi , Hsu, Michelle A. , Barham, Whitney , Hsu, Michelle, Zeng, Hu , Pavelko, Kevin D. , Mansfield, Aaron S. , Dong, Haidong

Mayo Clinic

No container title available | June 13, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1659209/v1 Get It

Abstract Seven different anti-PD-1 and PD-L1 monoclonal antibodies are now widely used in the US to treat a variety of cancer types, but there have been no clinical trials comparing them directly. Furthermore, because many of these antibodies do not cross react between mouse and human proteins, no preclinical models exist in which to consider these types of questions. Thus, we produced humanized PD-1 and PD-L1 mice in which the extracellular domains of both mouse PD-1 and PD-L1 were replaced with the corresponding human sequences. Using this new model, we sought to compare the strength of the immune response generated by FDA-approved antibodies. To do this, we performed an in vivo T cell priming assay in which anti-PD-1/L1 therapies were given at the time of T cell priming against surrogate tumor antigen (OVA), followed by subsequent B16-OVA tumor challenge. We found that anti-PD-1/L1-treated mice exhibited significantly better tumor rejection than controls, although both the control and antibody-treated mice generated comparable numbers of OVA-specific T cells at the time of priming. To determine what could mediate this strong antitumor immune response, we identified the increased production of CX3CR1+PD-1+CD8+ cytotoxic T cells in the anti-PD-1/L1-treated mice, the same subset of effector T cells known to increase in clinical responders to PD-1/L1 therapy. Thus, our model permits the direct comparison of FDA-approved anti-PD-1/L1 monoclonal antibodies and further correlates successful tumor rejection with the level of CX3CR1+PD-1+CD8 + T cells, making this model a critical tool for future studies to optimize and better utilize anti-PD-1/L1 therapeutics.
Multi‐ancestry genome‐wide association study of asthma exacerbations
Herrera‐Luis, Esther , Ortega, Victor E. , Ampleford, Elizabeth J., Granell, Raquel , Roos, Emmely W. de , Terzikhan, Natalie, Vergara, Ernesto Elorduy , Hernandez‐Pacheco, Natalia , Pérez-García, Javier , Martín-González, Elena , Lorenzo-Díaz, Fabián , Group, U‐BIOPRED Study, Jorgensen, Andrea , Forno, Erick , Lethem, Ryan, Espuela‐Ortiz, Antonio , Eng, Celeste , Pérez, José María Hernández , Hawkins, Greg, Marsico, Annalisa , Bahmer, Thomas , Hansen, Gesine , Kopp, Matthias , Rios, Raimon, Cruz, María Jesús , González‐Barcala, Francisco Javier , Olaguibel, José María , Canino, Glorisa , Cloutier, Michelle M. , Rodríguez‐Santana, José, Korta‐Murua, Javier , Potočnik, Uroš , Kabesch, Michael , Mukhopadhyay, Somnath , Pirmohamed, Munir , Hawcutt, Daniel B. , Palmer, Colin N.A. , Mutius, Erika von , Celedón, Juan C. , Chew, Fook Tim , Bleecker, Eugene R. , Meyers, Deborah A. , Granell, Raquel , Hernandez-Pacheco, Natalia , Perez-Garcia, Javier , Lorenzo-Diaz, Fabian , Hashimoto, Simone , Yan, Qi , Forno, Erick , Vijverberg, Susanne J , Espuela-Ortiz, Antonio , Gorenjak, Mario , Hernández-Pérez, José M , Poza-Guedes, Paloma , Corcuera, Paula , Olaguibel, José María , Plaza, Vicente , Quirce, Santiago , Cloutier, Michelle , Del Pozo, Victoria , Figueiredo, Camila , Pirmohamed, Munir , Hawcutt, Daniel B , Melén, Erik , Palmer, Colin N A , Turner, Steve , Maitland-van der Zee, Anke H , von Mutius, Erika , Celedón, Juan C , Brusselle, Guy , Chew, Fook Tim , Burchard, Esteban G. , Pino-Yanes, Maria , Sio, Yang Yie , Brinkman, Paul , Group, U‐BIOPRED Study, González‐Pérez, Ruperto , Sardón‐Prado, Olaia , Rabe, Klaus Friedrich , Villar, Jesús

Mayo Clinic

Pediatric Allergy and Immunology | June 8, 2022 | Volume: 33 | Issue: 6 | Pages: No page available

10.1111/pai.13802 | PMID 35754128 Get It

Abstract Background Asthma exacerbations are a serious public health concern due to high healthcare resource utilization, work/school productivity loss, impact on quality of life, and risk of mortality. The genetic basis of asthma exacerbations has been studied in several populations, but no prior study has performed a multi‐ancestry meta‐analysis of genome‐wide association studies (meta‐GWAS) for this trait. We aimed to identify common genetic loci associated with asthma exacerbations across diverse populations and to assess their functional role in regulating DNA methylation and gene expression. Methods A meta‐GWAS of asthma exacerbations in 4989 Europeans, 2181 Hispanics/Latinos, 1250 Singaporean Chinese, and 972 African Americans analyzed 9.6 million genetic variants. Suggestively associated variants ( p ≤ 5 × 10 −5 ) were assessed for replication in 36,477 European and 1078 non‐European asthma patients. Functional effects on DNA methylation were assessed in 595 Hispanic/Latino and African American asthma patients and in publicly available databases. The effect on gene expression was evaluated in silico. Results One hundred and twenty‐six independent variants were suggestively associated with asthma exacerbations in the discovery phase. Two variants independently replicated: rs12091010 located at vascular cell adhesion molecule‐1/exostosin like glycosyltransferase‐2 ( VCAM1 / EXTL2 ) (discovery: odds ratio (OR T allele ) = 0.82, p = 9.05 × 10 −6 and replication: OR T allele = 0.89, p = 5.35 × 10 −3 ) and rs943126 from pantothenate kinase 1 ( PANK1 ) (discovery: OR C allele = 0.85, p = 3.10 × 10 −5 and replication: OR C allele = 0.89, p = 1.30 × 10 −2 ). Both variants regulate gene expression of genes where they locate and DNA methylation levels of nearby genes in whole blood. Conclusions This multi‐ancestry study revealed novel suggestive regulatory loci for asthma exacerbations located in genomic regions participating in inflammation and host defense.
Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription
Cho, Sung Dae, Jiang, Cheng , Malewicz, Barbara, Kang, Kyung‐Sun , Lee, Yong-Soon, Ip, Clement, Dong, Yan , Young, Charles Y.F. , Lü, Junxuan

Mayo Clinic

Molecular Cancer Therapeutics | June 8, 2022 | Volume: 3 | Issue: 5 | Pages: 605-612

10.1158/1535-7163.605.3.5 Get It

Abstract Prostate-specific antigen (PSA) is widely used clinically for prostate cancer diagnostics and as an indicator of therapeutic efficacy and recurrence. Several human chemoprevention trials are being conducted to validate the prostate cancer prevention efficacy of selenium and PSA is used in these trials as a biomarker of response. A better understanding of the effects of selenium metabolites on the kinetics of PSA turnover and secretion in prostate cancer cells treated with selenium at concentrations which are achievable physiologically will be important for interpreting the results of these trials. This study addresses whether the putative active anticancer selenium metabolite methylselenol or its precursor methylseleninic acid (MSeA) specifically inhibits PSA expression in the androgen-responsive LNCaP prostate cancer cell model. The results show that exposure to sub-apoptotic concentrations of MSeA and methylselenol inhibited PSA protein expression and secretion, whereas sodium selenite and selenomethionine lacked inhibitory effect. The inhibition was detectable at 3 h of exposure and required a threshold level of MSeA to sustain. Turnover experiments showed that MSeA caused rapid PSA degradation, which was partially blocked by lysosomal inhibitors, but not by a proteasomal inhibitor. Furthermore, MSeA treatment reduced PSA mRNA level, down-regulated androgen receptor protein expression, and inhibited androgen-stimulated PSA promoter transcription. In summary, methylselenol or MSeA specifically and rapidly inhibited PSA expression through two mechanisms of action: inducing PSA protein degradation and suppressing androgen-stimulated PSA transcription. These findings may have important mechanistic implications for the prostate specific cancer chemopreventive action of selenium.
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
Riely, Gregory J. , Heist, Rebecca S. , Pacheco, Jose M., Sabari, Joshua K. , Leventakos, Konstantinos , Yau, Edwin , Zhang, Jun , Velastegui, Karen , Christensen, James G. , Yan, Xiaohong , Anderes, Kenna , Jänne, Pasi A. , Spira, Alexander I. , Gadgeel, Shirish M. , Ou, Sai‐Hong Ignatius , Johnson, Melissa L. , Bazhenova, Lyudmila , Negrao, Marcelo Vailati , Pennell, Nathan A , Chao, Richard C.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 9002-9002

10.1200/jco.2022.40.16_suppl.9002 Get It

9002 Background: KRAS is a key mediator of the RAS/MAPK signaling cascade that promotes cellular growth and proliferation. KRASG12C mutation occurs in ̃14% of NSCLC. Adagrasib, an investigational agent, is a KRASG12C inhibitor that irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib is optimized for favorable pharmacokinetic (PK) properties, including long half-life (̃24 h), dose-dependent PK, and central nervous system penetration; it has demonstrated objective response and favorable tolerability in the Phase 1/1b setting. Methods: KRYSTAL-1 (NCT03785249) is a multicohort Phase 1/2 study evaluating adagrasib as monotherapy or in combination regimens in patients with advanced solid tumors harboring a KRASG12C mutation. Here we report the first disclosure from all patients enrolled in Cohort A, a Phase 2 cohort with registrational intent, evaluating adagrasib given 600 mg orally BID in patients with NSCLC previously treated with platinum-based chemotherapy and anti-PD-1/L1 therapy. Study objectives include evaluating efficacy (objective response rate [ORR], duration of response [DOR], progression-free survival [PFS], overall survival [OS]), safety, PK, and exploratory correlative analyses. Objective tumor response was assessed per RECIST v1.1 by blinded independent central review (BICR). Results: As of the 15 October 2021 data cutoff, 116 patients with NSCLC harboring a KRASG12C mutation were enrolled and treated, with a median follow-up of 12.5 months. Baseline characteristics include median age 64 years, 65% female, and 15.5%/83.6% with ECOG PS 0/1; 98.3% of patients received adagrasib following prior treatment with immunotherapy and chemotherapy, with a median of 2 prior systemic therapies. The ORR (by BICR) was 42.9% (48/112) and the disease control rate was 79.5% (89/112); 31 patients remain on treatment. Median DOR was 8.5 months (95% CI 6.2–13.8), median PFS was 6.5 months (95% CI 4.7–8.4), median OS was 12.6 months (95% CI 9.2–NE). Treatment-related AEs (TRAEs) of any grade occurred in 97.4% of patients, grade ≥3 TRAEs in 45.7%, 2 grade 5 TRAEs, and 8 (6.9%) TRAEs led to discontinuation. The most commonly reported (≥25%) TRAEs (any grade) were diarrhea (62.9%), nausea (62.1%), vomiting (47.4%), fatigue (40.5%), ALT/AST increased (27.6%/25%), blood creatinine increased (25.9%); the most commonly reported (≥5%) TRAEs (grade 3/4) were lipase increased (6%) and anemia (5.2%). Additional subgroup analyses will be presented, including selected demographics, molecular markers and sites of metastases. Conclusions: Adagrasib is well tolerated and demonstrates promising efficacy in pretreated patients with NSCLC harboring a KRASG12C mutation. A Phase 3 trial evaluating adagrasib monotherapy versus docetaxel in previously treated patients with KRASG12C-mutant NSCLC is ongoing (NCT04685135). Clinical trial information: NCT03785249.